Ipragliflozin
id:
ipragliflozin-216-4776797
title:
Ipragliflozin
text:
Ipragliflozin is a pharmaceutical drug for treatment of type 2 diabetes. Ipragliflozin, jointly developed by Astellas Pharma and Kotobuki Pharmaceutical, was approved in Japan on January 17, 2014, and in Russia on May 22, 2019. Ipragliflozin is a Sodium/glucose cotransporter 2 (SGLT2) inhibitor (gliflozin). These membrane proteins are on the cell surface and transfer glucose into the cells. SGLT2 is one subtype of SGLTs and plays a key role in the reuptake of glucose in the proximal tubule of th
brand slug:
wiki
category slug:
encyclopedia
description:
Chemical compound
original url:
https://en.wikipedia.org/wiki/Ipragliflozin
date created:
2015-08-22T19:26:31Z
date modified:
2024-09-13T00:39:22Z
main entity:
{"identifier":"Q17193526","url":"https://www.wikidata.org/entity/Q17193526"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/8/89/Haworth_projection_of_ipragliflozin.svg","width":512,"height":358}
fields total:
13
integrity:
16